Monitor for any upcoming earnings releases or clinical trial updates that may have prompted this timing; consider whether this reflects routine portfolio management or a signal of reduced confidence ahead of potential negative catalysts.
XENE drugs
XENE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 13 $55.23entry
- T+1 · 8mo ago −1.03%α −2.06% · $54.66
- T+5 · 8mo ago −0.53%α +1.59% · $54.94
- T+20 · 7mo ago +6.10%α +2.51% · $58.60
- T+60 · 5mo ago −7.28%α −18.89% · $51.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three executive insiders at Xenon Pharmaceuticals (XENE) sold shares worth over $550K in open-market transactions within a 2-day window, following the exercise of stock options. The sales represent a coordinated monetization of equity compensation, with the CEO accounting for over 70% of the total value sold.
Key Financial Metrics
Key Facts
- CEO Ian Mortimer sold $403,584 worth of shares in a single open-market transaction on March 13, 2026.
- Chief Legal Officer and Chief Medical Officer sold $74,112 and $77,867 respectively on March 13.
- All three executives exercised stock options (totaling 37,500 shares) on March 12 at $0 cost, immediately preceding the sales.
- Total open-market sales: $555,563 across 10,060 shares at $55.225 per share.
- Sales represent approximately 0.011% of XENE's $4.8B market cap, small in relative terms but concentrated among top executives.
Financial Impact
$555,563 in insider selling from option exercises and open-market dispositions
Risk Factors
- Perception of insider pessimism due to coordinated timing among C-suite executives.
- Potential for short-term downward pressure on share price due to sentiment impact despite modest dollar volume.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (9 trades, 7d window) | cluster-XENE-1773447432169 |
Track record
19 reports on XENE
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers